Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Transcriptional Regulation & Oncology Target Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ATP1B4 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ATP1B4 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View ATP1B4 Products |
| Gene Delivery | ATP1B4 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View ATP1B4 Products |
| Benchmark Ab | Anti-ATP1B4 Monoclonal Antibody Recombinant positive control for western blot and target localization. |
View ATP1B4 Products |
| Validator | ATP1B4 siRNA Set For specific knockdown verification and phenotypic assays. |
View ATP1B4 Products |
| Related Target A | ATP1A1 Alpha subunit counterpart in ATPase networks, utilized for selectivity benchmarking. |
View ATP1A1 Products |
| Related Target B | YY1 Transcriptional coregulator known to interact with nuclear ATP1B4. |
View YY1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subfamily Counter Screening | Homolog panel proteins (ATP1B1/2/3) strictly verified by mass spec to ensure no cross-reactivity. |
| Intracellular Localization Validation | Sequence-verified Promise-ORF clones ensuring native folding for accurate nuclear envelope targeting. |
| Lack of Valid Controls | Recombinant positive control antibodies included for reliable intracellular detection. |
| False Positives in Phenotypic Assays | Validated siRNA included for precise specificity checks in target-knockdown models. |
Live ATP1B4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
Unlike classical plasma membrane Na+/K+ ATPase subunits, ATP1B4 exhibits a unique evolutionary shift in placental mammals, localizing predominantly to the inner nuclear membrane where it functions in transcriptional regulation and cellular stress responses. The race for ATP1B4-targeted therapeutics is currently in the early preclinical discovery phase, with academic and biotech players shifting focus from traditional cell-surface targeting to intracellular modulation strategies like RNA interference (RNAi), antisense oligonucleotides (ASOs), and targeted protein degradation (PROTACs). As the biological role of ATP1B4 in specific oncology indications and muscle-development disorders becomes clearer, the next wave of R&D is targeting its highly specific protein-protein interactions (PPIs) within the nucleus.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| RNAi / ASO | Early Stage Biotech / Academic | Oncology, Myopathies | Target Knockdown Verification (Need high-efficiency Lentivirus / siRNA Sets) |
| PROTAC / Degrader | Preclinical Innovators | Solid Tumors | Ubiquitination Assays (Need High-Purity Recombinant Protein & Benchmark Abs) |
| Small Molecule Inhibitor | Discovery Stage Pharma | Transcriptional Dysregulation | Selectivity Assay (Need Homolog Panel Proteins to rule out ATP1B1/2/3 binding) |